Bioinformatic Studies for the Identification of Possible Therapeutic Targets in Amyotrophic Lateral Sclerosis (ALS) Disease

BIOINFORMATIC STUDIES FOR THE IDENTIFICATION OF POSSIBLE THERAPEUTIC TARGETS IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) DISEASE

Authors

  • Iván López Pérez Birkbeck Universidad de Londres, Departamento de Ciencias Biológicas
  • Alex Valencia Silva Universidad Técnica de Ambato, Facultad de Ciencia e Ingeniería en Alimentos y Biotecnología
  • Luis Varela Polit Universidad Internacional del Ecuador, Especialidad de Medicina Interna
  • Cristian Fernando Galarza Universidad Técnica de Ambato, Facultad de Ciencia e Ingeneiría en Alimentos y Biotecnología

DOI:

https://doi.org/10.31243/aci.v30i1.2034

Keywords:

ALS, Therapeutic Target, Computer Aided Drug Design.

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by the progressive loss of neurons in different areas of the central nervous system, which in a short time causes the death of the patient. Biological databases such as MalaCards, Online Mendelian Inheritance in Man (OMIM), Harmonizome and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used, the most relevant genes were grouped according to the dysfunction they cause in the genes and according to the score value assigned in each of them. Twenty-six elite genes were selected from which interaction networks were designed to identify the most important connections between the proteins synthesized by these genes. From these pathways, genes following SOD1 gene mutations were chosen to select the domains that meet the best drugability criteria and through a virtual screening the domains that offer the best conditions for ligand binding that could later be transformed into potential drugs were selected; these receptors were validated using the DrugBank database. The Valosin Containing Protein (VCP) and VAMP Associated Protein B and C (VAPB) genes were identified as the most important genes related to the disease, and the protein receptors Transitional endoplasmatic reticulum and Vesicle-associated membrane protein-associated protein B/C together with their targets, Saquinavir and Astemizole, two commercial drugs whose toxicological properties were analyzed to ensure their applicability. Saquinavir presented better properties in the evaluation of Quantitative Structure-Activity Ratio (QSAR) and Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties, on the other hand, Astemizole exhibited greater stability since it presents hydrogen bonding, which is responsible for providing this characteristic to the binding.

References

Okada, M., Yamashita, S., Ueyama, H., Ishizaki, M., Maeda, Y., & Ando, Y. (2018). Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci, 11, 11-14. https://doi.org/10.1016/j.ensci.2018.05.001

Pedretti, A., Mazzolari, A., Gervasoni, S., Fumagalli, L., & Vistoli, G. (2020). The VEGA suite of programs: an versatile platform for cheminformatics and drug design projects. Bioinformatics, 37(8), 1174-1175. https://doi.org/10.1093/bioinformatics/btaa774 %J Bioinformatics

Pires, D. E., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem, 58(9), 4066-4072. https://doi.org/10.1021/acs.jmedchem.5b00104

Pradhan, J., & Bellingham, M. C. J. B. S. (2021). Neurophysiological mechanisms underlying cortical hyper-excitability in amyotrophic lateral sclerosis: A review. 11(5), 549.

Ralli, M., Lambiase, A., Artico, M., de Vincentiis, M., & Greco, A. J. T. I. M. A. J. I. (2019). Amyotrophic Lateral Sclerosis: Autoimmune Pathogenic Mechanisms, Clinical Features, and Therapeutic Perspectives. 21(7), 438-443.

Downloads

Published

2023-06-26

Issue

Section

Artículos de investigación

How to Cite

Bioinformatic Studies for the Identification of Possible Therapeutic Targets in Amyotrophic Lateral Sclerosis (ALS) Disease: BIOINFORMATIC STUDIES FOR THE IDENTIFICATION OF POSSIBLE THERAPEUTIC TARGETS IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) DISEASE. (2023). Alimentos Ciencia E Ingeniería, 30(1), 1-26. https://doi.org/10.31243/aci.v30i1.2034

Similar Articles

You may also start an advanced similarity search for this article.